Roche's 3rd Quarter Sales 2003 release
September 16, 2003 02:41 ET
|
F. Hoffmann-La Roche AG
BASEL, Switzerland, Sept. 16, 2003 (PRIMEZONE) -- Roche (Other OTC:RHHBY) will publish its sales results for the 3rd Quarter of 2003 at 07.00h (CET) on
Thursday, 16th October...
Invitation Teleconference -- Active Biotech AB
September 16, 2003 01:51 ET
|
Active Biotech
STOCKHOLM, Sweden, Sept. 16, 2003 (PRIMEZONE) -- With reference to today's press release regarding results from Phase II study of Active Biotech's (Other OTC:ACTBF) laquinimod (SAIK-MS), we hereby...
Primary endpoint reached in Phase II clinical trial of Active Biotech's substance for oral treatment of multiple sclerosis
September 16, 2003 01:45 ET
|
Active Biotech
STOCKHOLM, Sweden, Sept. 16, 2003 (PRIMEZONE) -- A first analysis of the main parameters in Active Biotech's (Other OTC:ACTBF) clinical Phase II study with laquinimod (SAIK-MS) for oral treatment of...
Invitation Teleconference - Active Biotech AB
September 16, 2003 01:36 ET
|
Active Biotech
To participate in the teleconference, please call +44 207 162 0192.
To listen at the teleconference please visit www.activebiotech.com.
To listen to the teleconference afterwards,...
Inbjudan Telekonferens - Active Biotech AB
September 16, 2003 01:35 ET
|
Active Biotech
För att delta i telefonkonferensen, v.v ring +44 207 162 0192.
För att lyssna på telefonkonferensen: besök www.activebiotech.com.
Vill ni lyssna på telefonkonferensen i...
Primary endpoint reached in Phase II clinical trial of Active Biotech's substance for oral treatment of multiple sclerosis
September 16, 2003 01:31 ET
|
Active Biotech
The results indicate that patients treated with 0.3 mg/day of laquinimod showed a statistically significant reduction in MRI activity of 30% compared with patients who received a non-active substance...
Prexige approved in the United Kingdom
September 16, 2003 01:30 ET
|
Novartis Pharma AG
Prexige® (lumiracoxib), a novel COX-2 selective inhibitor approved in the United Kingdom
Basel, 16 September 2003 - Novartis announced today that Prexige® (lumiracoxib), a novel COX-2...
Active Biotechs orala substans för behandling av multipel skleros uppnår primärt mål i klinisk fas II-prövning
September 16, 2003 01:30 ET
|
Active Biotech
Resultatet visar att patienter som behandlats med laquinimod 0.3 mg/dag uppvisade en statistiskt signifikant minskning av MRI-aktivitet med cirka 30% jämfört med patienter som erhållit icke aktivt...
Glancy & Binkow LLP Commences Class Action Lawsuit and Seeks to Recover Losses for Investors Who Purchased Janus Mutual Funds -- JNS
September 15, 2003 20:00 ET
|
Glancy Binkow & Goldberg LLP
LOS ANGELES, Sept. 15, 2003 (PRIMEZONE) -- Notice is hereby given that Glancy & Binkow LLP commenced a Class Action lawsuit in the United States District Court for the Southern District of New...
Chitwood & Harley LLP Charges Check Point Software Technologies Inc. and Certain of Its Officers and/or Directors with Securities Fraud in Suit Brought on Behalf of CHKP Purchasers Between July 10, 2001 and April 4, 2002 -- CHKP
September 15, 2003 18:18 ET
|
Chitwood & Harley
ATLANTA, Sept. 15, 2003 (PRIMEZONE) -- Chitwood & Harley announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, on behalf...
- August 15, 2024 06:04 ET Global Battery Energy Storage System Market Forecast to 2029: Increasing Opportunities in Rural Electrification Projects Worldwide and Rising Demand for Power Supply from Data Centers
- August 15, 2024 05:49 ET Automotive Vacuumless Braking Market Report 2024 - Increased Focus on Lightweight Vehicle Components Strengthens Business Case for Vacuumless Brakes